TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24559843

Group type: EXPERIMENTAL
Intervention: Baseline physical activity (measured by pedometer records)
Number of subjects: 9306

Group type: EXPERIMENTAL
Intervention: Diet behavior (self-reported on a 6-item survey)
Number of subjects: 9306
Study: 24560330

Group type: EXPERIMENTAL
Intervention: Axitinib 5mg for up to 12 weeks
Number of subjects: 24
Study: 24561125

Group type: EXPERIMENTAL
Intervention: Liraglutide 1.2 mg once daily
Number of subjects: 2792

Group type: EXPERIMENTAL
Intervention: Liraglutide 1.8 mg once daily
Number of subjects: 2792

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2792

Group type: EXPERIMENTAL
Intervention: Liraglutide 1.8 mg
Number of subjects: 2792

Group type: EXPERIMENTAL
Intervention: Liraglutide 1.2 mg and 1.8 mg
Number of subjects: 2792
Study: 24561146

Group type: EXPERIMENTAL
Intervention: Recovery of normal LV function and size after treatment
Number of subjects: 868

Group type: EXPERIMENTAL
Intervention: Death or heart transplantation
Number of subjects: 868

Group type: EXPERIMENTAL
Intervention: Persistently abnormal echocardiograms
Number of subjects: 868

Group type: EXPERIMENTAL
Intervention: Predictors of normalization
Number of subjects: 868

Group type: EXPERIMENTAL
Intervention: Heart transplantation or death after normalization
Number of subjects: 868
Study: 24562448

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiotherapy with docetaxel (40 mg/m²), cisplatin (40 mg/m²), and panitumumab (6 mg/kg) with radiation therapy (5040 cGy, 180 cGy/day × 28 days) starting week 5.
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiotherapy with docetaxel, cisplatin, and panitumumab.
Number of subjects: 70
Study: 24562641

Group type: EXPERIMENTAL
Intervention: FDG PET/CT during radiotherapy (mean dose 43 Gy)
Number of subjects: 52
Study: 24563078

Group type: EXPERIMENTAL
Intervention: Continuous-infusion topotecan (0.4 mg/m² per day for 9-10 days every 3 weeks) with erlotinib (150 mg orally on days 1-10 of each cycle)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Continuous-infusion topotecan with erlotinib
Number of subjects: 6
Study: 24563419

Group type: EXPERIMENTAL
Intervention: Rigorous cardiovascular disease risk reduction program
Number of subjects: 63

Group type: COMPARATOR
Intervention: Prescription medications
Number of subjects: 63

Group type: COMPARATOR
Intervention: Controls (matched participants)
Number of subjects: 63
Study: 24563480

Group type: EXPERIMENTAL
Intervention: PM01183 (4.0 mg/m(2) recommended dose)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: PM01183 (7.0 mg flat dose)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: PM01183 (recommended dose)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: PM01183 (at or above recommended dose)
Number of subjects: 31
Study: 24563690

Group type: EXPERIMENTAL
Intervention: Intermittent rhythm monitoring (IRM) of various durations (24-hour, 7-day, 14-day, 30-day)
Number of subjects: 647

Group type: EXPERIMENTAL
Intervention: Intermittent rhythm monitoring (IRM) of shorter duration (24-hour)
Number of subjects: 647
Study: 24563781

Group type: EXPERIMENTAL
Intervention: Duloxetine treatment for 12 weeks
Number of subjects: 30
Study: 24564178

Group type: EXPERIMENTAL
Intervention: CRP levels in patients without diabetes mellitus who are not receiving statin therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CRP levels in the overall population
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CRP levels in women and those at higher cardiovascular risk
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CRP levels in patients with metabolic syndrome markers
Number of subjects: 0
Study: 24564281

Group type: EXPERIMENTAL
Intervention: MRI in stable CF patients
Number of subjects: 50

Group type: COMPARATOR
Intervention: MRI in non-CF control subjects
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: MRI in CF patients with exacerbations before treatment
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: MRI in CF patients with exacerbations after antibiotic therapy
Number of subjects: 50
Study: 24565221

Group type: EXPERIMENTAL
Intervention: Saxagliptin 2.5 mg BID plus metformin
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo plus metformin
Number of subjects: 160
Study: 24566706

Group type: EXPERIMENTAL
Intervention: PF-03446962 10 mg/Kg intravenously fortnightly until disease progression or unacceptable toxicity
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: PF-03446962
Number of subjects: 14
Study: 24566733

Group type: EXPERIMENTAL
Intervention: Aspirin 100 mg once daily for 2 and 4 weeks
Number of subjects: 18
Study: 24567125

Group type: EXPERIMENTAL
Intervention: Hypocaloric dietary pattern for 8 weeks
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Baseline irisin levels above the median
Number of subjects: 96
Study: 24567804

Group type: EXPERIMENTAL
Intervention: Benchmarking
Number of subjects: 797
Study: 24567843

Group type: EXPERIMENTAL
Intervention: MenACWY-TT (lot A)
Number of subjects: 1016

Group type: COMPARATOR
Intervention: MenACWY-DT
Number of subjects: 1016
Study: 24568177

Group type: EXPERIMENTAL
Intervention: Ziprasidone 40-160 mg/day
Number of subjects: 114
Study: 24568613

Group type: EXPERIMENTAL
Intervention: Inhaled LPS (20,000 endotoxin units) in healthy nonsmokers
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Inhaled LPS (20,000 endotoxin units) in mild smokers
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Inhaled LPS (20,000 endotoxin units) in both groups
Number of subjects: 30
Study: 24569099

Group type: EXPERIMENTAL
Intervention: Once-daily perphenazine dosing
Number of subjects: 257

Group type: COMPARATOR
Intervention: Twice-daily perphenazine dosing
Number of subjects: 257
Study: 24569424

Group type: EXPERIMENTAL
Intervention: Palmar fasciectomy
Number of subjects: 26
Study: 24569817

Group type: EXPERIMENTAL
Intervention: Elevated levels of hemoglobin A1c (HbA1c)
Number of subjects: 512

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 512

Group type: EXPERIMENTAL
Intervention: Arterial hypertension
Number of subjects: 512
Study: 24569816

Group type: EXPERIMENTAL
Intervention: Good collateral flow (collateral score 3-4)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Poor collateral flow (collateral score 0-2)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Poor collaterals who reperfused (TICI 2B-3)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Poor collaterals versus good collaterals
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Poor reperfusion (TICI 0-2a) with poor collaterals
Number of subjects: 60
Study: 24570910

Group type: EXPERIMENTAL
Intervention: Lower energy nutritional supply (42 kJ/kg/d) in experimental group
Number of subjects: 95

Group type: COMPARATOR
Intervention: Routine permissive underfeeding nutritional supply (75 kJ/kg/d) in control group
Number of subjects: 95
Study: 24571550

Group type: EXPERIMENTAL
Intervention: Auto Intervention (EHR-embedded program for mailing FIT kits)
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Auto Plus Intervention (mailed FIT kit plus tailored interventions)
Number of subjects: 206

Group type: COMPARATOR
Intervention: Usual Care (passive control)
Number of subjects: 206
Study: 24571752

Group type: EXPERIMENTAL
Intervention: cfDNA testing
Number of subjects: 1914

Group type: COMPARATOR
Intervention: Standard screening
Number of subjects: 1914
Study: 24571916

Group type: EXPERIMENTAL
Intervention: Desvenlafaxine 50 mg/d
Number of subjects: 2156

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2156
Study: 24571940

Group type: EXPERIMENTAL
Intervention: NLR ≥5
Number of subjects: 432

Group type: COMPARATOR
Intervention: NLR <5
Number of subjects: 432

Group type: COMPARATOR
Intervention: Low tertile NLR
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: High tertile NLR
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: Middle tertile NLR
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: Diabetes mellitus
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: Statin use
Number of subjects: 432
Study: 24572562

Group type: EXPERIMENTAL
Intervention: Breastfed infants
Number of subjects: 70

Group type: COMPARATOR
Intervention: Formula-fed infants
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: All feeding groups (pooled analysis)
Number of subjects: 70
Study: 24573552

Group type: EXPERIMENTAL
Intervention: Ultra low-dose IL-2 (100,000-200,000 IU/m(2) ×3 per week for 6 to 12 weeks)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Ultra low-dose IL-2
Number of subjects: 16
Study: 24574239

Group type: EXPERIMENTAL
Intervention: Ipilimumab, an antagonist of CTLA-4
Number of subjects: 2
Study: 24574344

Group type: EXPERIMENTAL
Intervention: In vitro migration of CD45(dim)CD34(pos)CXCR4(pos)KDR(pos) cells
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Doubling of migrated cell counts
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Basal cell counts and migratory activity
Number of subjects: 119
Study: 24574776

Group type: EXPERIMENTAL
Intervention: FIT1
Number of subjects: 779

Group type: EXPERIMENTAL
Intervention: FITmax
Number of subjects: 779
Study: 24576165

Group type: EXPERIMENTAL
Intervention: T-BiRD regimen (thalidomide 100 mg/day, lenalidomide 25 mg/day, dexamethasone 40 mg/day, clarithromycin 500 mg twice daily)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: T-BiRD regimen
Number of subjects: 26
Study: 24576311

Group type: EXPERIMENTAL
Intervention: Sunitinib (50 mg/day for 4 weeks, followed by 2 weeks off treatment in repeated 6-week cycles)
Number of subjects: 4471
Study: 24576516

Group type: EXPERIMENTAL
Intervention: Dabigatran
Number of subjects: 56000

Group type: COMPARATOR
Intervention: Vitamin K antagonists (VKA)
Number of subjects: 56000
Study: 24576792

Group type: EXPERIMENTAL
Intervention: Sayana® Press (SP)
Number of subjects: 86

Group type: COMPARATOR
Intervention: DMPA IM
Number of subjects: 86
Study: 24576794

Group type: EXPERIMENTAL
Intervention: Levonorgestrel (LNG) 150 mcg/ethinyl estradiol (EE) 20 mcg for 42 days, LNG 150 mcg/EE 25 mcg for 21 days, LNG 150 mcg/EE 30 mcg for 21 days and EE 10 mcg for 7 days
Number of subjects: 3701

Group type: EXPERIMENTAL
Intervention: Levonorgestrel/ethinyl estradiol combined oral contraceptive
Number of subjects: 3701
Study: 24576876

Group type: EXPERIMENTAL
Intervention: Cold Pressor Test (CPT)
Number of subjects: 63
Study: 24576889

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 24577061

Group type: EXPERIMENTAL
Intervention: Healthy young men
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Healthy older men
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Type 2 diabetic patients
Number of subjects: 45
Study: 24577164

Group type: EXPERIMENTAL
Intervention: Bevacizumab added to chemotherapy
Number of subjects: 39
Study: 24577564

Group type: EXPERIMENTAL
Intervention: Classic PCD with situs ambiguus (SA)
Number of subjects: 767

Group type: COMPARATOR
Intervention: Control participants with situs ambiguus (SA)
Number of subjects: 767
Study: 24577748

Group type: EXPERIMENTAL
Intervention: BRAFi after IT (N = 32)
Number of subjects: 274

Group type: COMPARATOR
Intervention: BRAFi initially (N = 242)
Number of subjects: 274

Group type: COMPARATOR
Intervention: BRAFi discontinuation (N = 193)
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Ipilimumab after BRAFi discontinuation (N = 40)
Number of subjects: 274
Study: 24579662

Group type: EXPERIMENTAL
Intervention: CNS hemangioblastomas in VHL patients
Number of subjects: 225
Study: 24579886

Group type: EXPERIMENTAL
Intervention: Sumatriptan-naproxen
Number of subjects: 621

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 621
Study: 24579926

Group type: EXPERIMENTAL
Intervention: Everolimus 10 mg/d
Number of subjects: 58
Study: 24579987

Group type: EXPERIMENTAL
Intervention: Nobori biolimus-eluting stent (BES)
Number of subjects: 0

Group type: COMPARATOR
Intervention: First-generation drug-eluting stents (DES)
Number of subjects: 0
Study: 24581147

Group type: EXPERIMENTAL
Intervention: CT air trapping criteria (specifically E/I MLD ratio)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: CT air trapping criteria (LAA for the range -850 -1024 HU)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: CT air trapping criteria (LAA for the range -850 -910 HU)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: CT air trapping criteria (Expiratory to inspiratory MLD ratio)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: CT air trapping criteria
Number of subjects: 89
Study: 24581550

Group type: EXPERIMENTAL
Intervention: Suicidal threats
Number of subjects: 1460

Group type: EXPERIMENTAL
Intervention: Suicidal attempts
Number of subjects: 1460
Study: 24581956

Group type: EXPERIMENTAL
Intervention: Flexible insulin therapy (FIT) educational programme
Number of subjects: 30
Study: 24582005

Group type: EXPERIMENTAL
Intervention: ADOS (Autism Diagnostic Observation Schedule) module 1
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: ADOS score
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Bayley Scales of Infant Development-Third Edition
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: ASD-like social behaviors
Number of subjects: 21
Study: 24582503

Group type: EXPERIMENTAL
Intervention: Service satisfaction
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Social support
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Baseline QOL scores
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Symptoms' severity
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Spiritual well-being
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Level of activity
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 139
Study: 24582505

Group type: EXPERIMENTAL
Intervention: Vemurafenib 960 mg orally twice a day
Number of subjects: 3226
Study: 24582522

Group type: EXPERIMENTAL
Intervention: Live-donor uterus transplantation (UTx) with low-dose induction immunosuppression
Number of subjects: 9
Study: 24582673

Group type: EXPERIMENTAL
Intervention: Standardized nutrient drink (first part)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Gastric emptying of solids (second part)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Gastric emptying of liquids (second part)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Standardized nutrient drink (third part)
Number of subjects: 20
Study: 24583293

Group type: EXPERIMENTAL
Intervention: High-sensitivity cardiac troponin T (cTnT) assay
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Hourly sampling of cTnT
Number of subjects: 23
Study: 24583305

Group type: EXPERIMENTAL
Intervention: Transradial access (TRA) with normal AT results
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Transradial access (TRA) with intermediate AT results
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Transradial access (TRA) with abnormal AT results
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Transradial access (TRA) across all AT results
Number of subjects: 203
Study: 24583566

Group type: EXPERIMENTAL
Intervention: Risperidone long-acting injectable (RLAI)
Number of subjects: 522
Study: 24583795

Group type: EXPERIMENTAL
Intervention: MK-2206 (200 mg weekly)
Number of subjects: 19
Study: 24583822

Group type: EXPERIMENTAL
Intervention: 5-azacitidine (AZA)
Number of subjects: 63
Study: 24584086

Group type: EXPERIMENTAL
Intervention: Roche High-Pure-System/COBAS(®) TaqMan(®) v2.0 assay (HPS)
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Abbott realtime assay (ART)
Number of subjects: 290

Group type: COMPARATOR
Intervention: Comparison of HPS and ART
Number of subjects: 290

Group type: COMPARATOR
Intervention: RGT assessment based on ART
Number of subjects: 290
Study: 24584349

Group type: EXPERIMENTAL
Intervention: Fludarabine plus cyclophosphamide
Number of subjects: 555

Group type: COMPARATOR
Intervention: Fludarabine
Number of subjects: 555

Group type: COMPARATOR
Intervention: Chlorambucil
Number of subjects: 555
Study: 24585398

Group type: EXPERIMENTAL
Intervention: Moderate to Severe Household Hunger (MSHH)
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Exclusive Breastfeeding (EBF) at 6 months
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Breastfeeding (BF) at 12 months
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Exclusive Breastfeeding (EBF) between 4 and 6 months
Number of subjects: 178
Study: 24585508

Group type: EXPERIMENTAL
Intervention: Hybrid percutaneous coronary intervention (PCI) for ISR CTOs
Number of subjects: 521

Group type: COMPARATOR
Intervention: Hybrid percutaneous coronary intervention (PCI) for de novo CTOs
Number of subjects: 521

Group type: EXPERIMENTAL
Intervention: Hybrid PCI for ISR CTOs
Number of subjects: 521

Group type: COMPARATOR
Intervention: Hybrid PCI for de novo CTOs
Number of subjects: 521
Study: 24585716

Group type: EXPERIMENTAL
Intervention: Mechanical alternans (MA)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: T-wave alternans (TWA)
Number of subjects: 133
Study: 24585866

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 24586226

Group type: EXPERIMENTAL
Intervention: TG1042 (adenovirus-interferon-γ)
Number of subjects: 13
Study: 24586911

Group type: EXPERIMENTAL
Intervention: Viral transmission clusters (VTCs) identified through phylogenetic analysis and ultra-deep sequencing.
Number of subjects: 690

Group type: EXPERIMENTAL
Intervention: Viral transmission clusters (VTCs)
Number of subjects: 690

Group type: COMPARATOR
Intervention: Antiretroviral therapy
Number of subjects: 690
Study: 24587068

Group type: EXPERIMENTAL
Intervention: Psycho-educational intervention delivered by peer health workers (PHW); included a computer-assisted pre-test, educational video session, and a 6-week group program with weekly meetings.
Number of subjects: 200
Study: 24587318

Group type: EXPERIMENTAL
Intervention: Individual depressive symptoms (e.g., sad mood, concentration problems)
Number of subjects: 3703
Study: 24588403

Group type: EXPERIMENTAL
Intervention: Group interventions for alcohol/drug dependence and MDD
Number of subjects: 197
Study: 24589036

Group type: EXPERIMENTAL
Intervention: Periventricular white matter hyperintensities (PVWMHs)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Synergistic interactions of WMHs with lacunes
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Anterior PVWMHs
Number of subjects: 150
Study: 24589294

Group type: EXPERIMENTAL
Intervention: Etravirine 5.2 mg/kg (maximum dose 200 mg) twice a day (bid) plus optimized background regimen (OBR)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Etravirine 5.2 mg/kg bid plus OBR
Number of subjects: 101
Study: 24589669

Group type: EXPERIMENTAL
Intervention: GERD patients
Number of subjects: 48
Study: 24590637

Group type: EXPERIMENTAL
Intervention: Nivolumab (intravenous, every 2 weeks for up to 96 weeks)
Number of subjects: 107
Study: 24590653

Group type: EXPERIMENTAL
Intervention: High levels of TH mRNA in PB at diagnosis
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: High levels of PHOX2B mRNA in PB at diagnosis
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: High levels of TH, PHOX2B, or DCX mRNA in PB or BM at diagnosis
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: High levels of TH, PHOX2B, or DCX mRNA in BM after induction therapy
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: High TH (log10TH > 0.8) or high PHOX2B (log10PHOX2B > 0.28) in PB
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Magnitude of reduction in mRNA level between diagnosis and postinduction therapy in BM or PB
Number of subjects: 290
Study: 24590680

Group type: EXPERIMENTAL
Intervention: bovine lactoferrin (bLf) 100 mg twice a day
Number of subjects: 295

Group type: COMPARATOR
Intervention: ferrous sulphate 520 mg once a day
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: bovine lactoferrin (bLf)
Number of subjects: 295

Group type: COMPARATOR
Intervention: ferrous sulphate
Number of subjects: 295
Study: 24591834

Group type: EXPERIMENTAL
Intervention: Galantamine
Number of subjects: 2045

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2045
Study: 24593248

Group type: EXPERIMENTAL
Intervention: Initial antibiotic treatment modification (n = 589; 28.9%)
Number of subjects: 2030

Group type: COMPARATOR
Intervention: No initial antibiotic treatment modification
Number of subjects: 2030
Study: 24593656

Group type: EXPERIMENTAL
Intervention: Access to an interactive online care platform for self-management of diabetes.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Access to laboratory results and educational modules on diabetes through the online platform.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Economic analyses related to the use of the online platform.
Number of subjects: 0
Study: 24593819

Group type: EXPERIMENTAL
Intervention: 10 g Osteoset® T with 4% tobramycin sulfate
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 20 g Osteoset® T with 4% tobramycin sulfate
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Osteoset® T (10 g, 30 g, and 50 g)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Osteoset® T
Number of subjects: 12
Study: 24594550

Group type: COMPARATOR
Intervention: Overweight patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Obese patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Morbidly obese patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Morbidly obese patients without CT scanning
Number of subjects: 0

Group type: COMPARATOR
Intervention: Morbidly obese patients with CT scanning
Number of subjects: 0
Study: 24594870

Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (TDF) 300 mg once daily for 48 weeks
Number of subjects: 90
Study: 24595069

Group type: EXPERIMENTAL
Intervention: Oramorph (5 mg every 6 hours)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Morphine (M)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: M6G/M ratio
Number of subjects: 52
Study: 24595221

Group type: EXPERIMENTAL
Intervention: Mediterranean diet (MedDiet) for 4 weeks
Number of subjects: 70
Study: 24595454

Group type: EXPERIMENTAL
Intervention: GIP regimen (gemcitabine 1000 mg/m² on days 1 and 5, ifosfamide 1200 mg/m²/day on days 1-5, cisplatin 20 mg/m²/day on days 1-5, granulocyte colony-stimulating factor 263 μg/day on days 7-15, repeated every 3 weeks for four cycles)
Number of subjects: 37
Study: 24595532

Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement (TAVR)
Number of subjects: 64
Study: 24595628

Group type: EXPERIMENTAL
Intervention: Insulin analog therapy
Number of subjects: 66726

Group type: EXPERIMENTAL
Intervention: Baseline HbA1c level
Number of subjects: 66726

Group type: EXPERIMENTAL
Intervention: Geographical region
Number of subjects: 66726

Group type: EXPERIMENTAL
Intervention: End-of-study hypoglycemia (insulin-naive group)
Number of subjects: 66726

Group type: EXPERIMENTAL
Intervention: Insulin dose
Number of subjects: 66726

Group type: EXPERIMENTAL
Intervention: Health-related quality of life
Number of subjects: 66726